Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Finished Goods (2018 - 2022)

AVITA Medical's Finished Goods history spans 5 years, with the latest figure at $610000.0 for Q4 2022.

  • For Q4 2022, Finished Goods fell 16.89% year-over-year to $610000.0; the TTM value through Dec 2022 reached $610000.0, down 16.89%, while the annual FY2022 figure was $610000.0, N/A changed from the prior year.
  • Finished Goods reached $610000.0 in Q4 2022 per RCEL's latest filing, down from $734000.0 in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $734000.0 in Q4 2021 to a low of $132212.7 in Q2 2019.
  • Average Finished Goods over 5 years is $393920.7, with a median of $354655.7 recorded in 2018.
  • Peak YoY movement for Finished Goods: tumbled 53.66% in 2019, then surged 138.2% in 2021.
  • A 5-year view of Finished Goods shows it stood at $285311.3 in 2018, then crashed by 53.66% to $132212.7 in 2019, then soared by 34.63% to $178000.0 in 2020, then surged by 312.36% to $734000.0 in 2021, then decreased by 16.89% to $610000.0 in 2022.
  • Per Business Quant, the three most recent readings for RCEL's Finished Goods are $610000.0 (Q4 2022), $734000.0 (Q4 2021), and $424000.0 (Q2 2021).